AZD-1390

Experimental drug for cancer treatment

{{Drugbox | verifiedfields = changed | verifiedrevid = 477002548 | IUPAC_name = (2S)-2-[[4-[(3R)-3-methylmorpholin-4-yl]pyrimidin-2-yl]amino]-N-[(1S)-1-phenylethyl]propanamide | image = AZD-1390.svg | image2 = | width = 200 }}

AZD-1390 is an experimental pharmaceutical drug developed for the treatment of cancer. It is a potent and selective inhibitor of the ATM serine/threonine kinase (ATM), which plays a critical role in the DNA damage response (DDR) pathway. By inhibiting ATM, AZD-1390 aims to enhance the effectiveness of radiotherapy and chemotherapy in cancer treatment.

Mechanism of Action

AZD-1390 chemical structure

AZD-1390 functions by targeting the ATM kinase, a key regulator in the DDR pathway. The ATM protein is activated in response to DNA double-strand breaks, a type of damage that can be induced by ionizing radiation and certain chemotherapeutic agents. Once activated, ATM phosphorylates several downstream proteins that facilitate DNA repair, cell cycle arrest, and apoptosis. By inhibiting ATM, AZD-1390 prevents the repair of DNA damage in cancer cells, thereby enhancing the cytotoxic effects of DNA-damaging treatments.

Development and Clinical Trials

AZD-1390 is being developed by AstraZeneca, a global biopharmaceutical company. The drug is currently undergoing clinical trials to evaluate its safety, tolerability, and efficacy in combination with radiotherapy and chemotherapy. Early-phase trials have shown promising results, indicating that AZD-1390 can effectively sensitize tumors to radiation.

Potential Applications

The primary application of AZD-1390 is in the treatment of solid tumors, particularly those that are resistant to conventional therapies. By inhibiting the ATM pathway, AZD-1390 may overcome resistance mechanisms and improve patient outcomes. The drug is also being investigated for its potential use in glioblastoma, a highly aggressive form of brain cancer that is notoriously difficult to treat.

Challenges and Considerations

While AZD-1390 shows promise, there are several challenges associated with its development. One major concern is the potential for increased toxicity when combined with DNA-damaging agents. Careful dose optimization and patient selection are crucial to minimize adverse effects. Additionally, the development of resistance to ATM inhibitors is a potential issue that requires further investigation.

Related Pages

• ATM serine/threonine kinase
• DNA damage response
• Radiotherapy
• Chemotherapy
• Glioblastoma